Table 3.
PLCE1 haplotype and risk of SCCHN arising at non-oropharyngeal sites
| Haplotype frequencies | |||||||
|---|---|---|---|---|---|---|---|
| PLCE1 haplotypes a | Cases (N = 1,068) | Controls (N = 2,134) | Crude OR (95% CI) | Adjusted OR b (95% CI) | P b | ||
| N | % | N | % | ||||
| TAA | 572 | 53.6 | 1131 | 53.0 | 1.00 | 1.00 | |
| GAA | 128 | 12.0 | 318 | 14.9 | 0.80 (0.63-1.00) | 0.72 (0.56-0.92) | 0.008 |
| TGA | 119 | 11.1 | 198 | 9.3 | 1.19 (0.93-1.52) | 1.31 (1.00-1.72) | 0.049 |
| GGG | 87 | 8.1 | 179 | 8.4 | 0.96 (0.73-1.27) | 0.96 (0.71-1.29) | 0.771 |
| TGG | 96 | 9.0 | 170 | 8.0 | 1.12 (0.85-1.46) | 1.10 (0.82-1.46) | 0.528 |
| GGA | 66 | 6.2 | 138 | 6.5 | 0.95 (0.69-1.29) | 0.85 (0.61-1.18) | 0.334 |
a The alleles of haplotypes were arrayed as the location of the SNPs in PLCE1 stand from 5' to 3' (e.g. TAA denotes Trs11599672Ars2274223Ars3203713).
b Adjusted for age, gender, smoking and alcohol status in logistic models.